

# **The Medicines Company Dk ApS**

**c/o BRANDT revision, Ved Vesterport 6, 5., 1612 København V**

**Company reg. no. 40 25 93 17**

## **Annual report**

**11 February - 31 December 2019**

The annual report was submitted and approved by the general meeting on the 29 December 2020.

---

**Birgitte Stenbjerre**  
Chairman of the meeting

Notes:

- To ensure the greatest possible applicability of this document, IAS/IFRS British English terminology has been used.
- Please note that decimal points have not been used in the usual English way. This means that for instance DKK 146.940 means the amount of DKK 146,940, and that 23,5 % means 23.5 %.

## Contents

---

	<u>Page</u>
<b>Reports</b>	
Management's report	1
Auditor's report on compilation of the financial statements	2
<b>Company information</b>	
Company information	3
<b>Financial statements 11 February - 31 December 2019</b>	
Income statement	4
Statement of financial position	5
Notes	6

## **Management's report**

---

Today, the executive board has presented the annual report of The Medicines Company Dk ApS for the financial year 11 February - 31 December 2019.

The annual report has been presented in accordance with the Danish Financial Statements Act.

We consider the accounting policies appropriate and, in our opinion, the financial statements provide a fair presentation of the company's assets, equity and liabilities, and financial position at 31 December 2019 and of the company's results of activities in the financial year 11 February – 31 December 2019.

The executive board consider the conditions for audit exemption of the 2019 financial statements to be met.

We recommend that the annual report be approved by the general meeting.

Copenhagen, 29 December 2020

### **Executive board**

Carsten Gleerup

Peter Drøidal

## **Auditor's report on compilation of the financial statements**

---

### **To the shareholders of The Medicines Company Dk ApS**

We have compiled the financial statements of The Medicines Company Dk ApS for the financial year 11 February - 31 December 2019 based on the company's bookkeeping and on further information provided by you.

The financial statements comprise the income statement, statement of financial position, notes.

We performed this engagement in accordance with the international standard ISRS 4410 applying to compilation engagements.

We have applied our professional expertise to assist you in the preparation and presentation of the financial statements in accordance with the Danish Financial Statements Act. We have complied with relevant requirements of the Danish Act on Approved Auditors and Audit Firms and with ethical requirements of the Danish Institute of State Authorised Public Accountants, including principles of integrity, objectivity, professional competence and due care.

The financial statements and the accuracy and completeness of the information used to compile them are your responsibility.

As a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information you provided to us in order to compile the financial statements. Accordingly, we express neither an audit opinion nor a review opinion as to whether the financial statements have been compiled in accordance with the Danish Financial Statements Act.

Copenhagen V, 29 December 2020

### **BRANDT**

State Authorized Public Accounting Firm  
Company reg. no. 25 49 21 45

Uffe Nikolajsen

State Authorised Public Accountant  
mne9163

## **Company information**

---

**The company**

The Medicines Company Dk ApS  
c/o BRANDT revision  
Ved Vesterport 6, 5.  
1612 København V

Company reg. no. 40 25 93 17  
Financial year: 11 February - 31 December

**Executive board**

Carsten Gleerup  
Peter Drøidal

**Auditors**

BRANDT  
Statsautoriseret Revisionspartnerselskab  
Ved Vesterport 6, 5. sal  
1612 København V

## **Income statement**

---

All amounts in DKK.

<u>Note</u>	11/2 2019 - 31/12 2019
<b>Gross loss</b>	<b>-41.218</b>
<b>Operating profit</b>	<b>-41.218</b>
<b>Pre-tax net profit or loss</b>	<b>-41.218</b>
<b>Profit or loss from ordinary activities after tax</b>	<b>-41.218</b>
<b>Net profit or loss for the year</b>	<b>-41.218</b>
<b>Proposed appropriation of net profit:</b>	
Allocated from retained earnings	-41.218
<b>Total allocations and transfers</b>	<b>-41.218</b>

## Statement of financial position

---

All amounts in DKK.

<u>Note</u>	<u>31/12 2019</u>
<b>Assets</b>	
<b>Current assets</b>	
Other receivables	31.595
Total receivables	<u>31.595</u>
<b>Total current assets</b>	<b><u>31.595</u></b>
<b>Total assets</b>	<b><u>31.595</u></b>
<b>Equity and liabilities</b>	
<b>Equity</b>	
3 Contributed capital	50.000
4 Retained earnings	<u>-41.218</u>
<b>Total equity</b>	<b><u>8.782</u></b>
<b>Liabilities other than provisions</b>	
Trade payables	<u>22.813</u>
Total short term liabilities other than provisions	<u>22.813</u>
<b>Total liabilities other than provisions</b>	<b><u>22.813</u></b>
<b>Total equity and liabilities</b>	<b><u>31.595</u></b>

**1 The significant activities of the enterprise**

**2 Micro enterprise**

## Notes

---

All amounts in DKK.

11/2 2019  
- 31/12 2019

---

**1. The significant activities of the enterprise**

The objective of the Company is to develop and commercialize pharmaceuticals, biotechnology and medical technology and related business.

**2. Micro enterprise**

The annual accounts are prepared in accordance with the rules for micro enterprises identified as accounting class B enterprises. In accordance with section 22 b of the Danish Financial Statements Act, we do not state information about the following issues:

- The accounting policies used
- Debt falling due after more than 5 years
- Reversal of writedown of current assets
- Writedown of current assets exceeding usual writedown
- Average number of full-time employees during the financial year

Der specificeres således:

**3. Contributed capital**

Contributed capital 11 February 2019	50.000
	<b>50.000</b>

**4. Retained earnings**

Retained earnings for the year	-41.218
	<b>-41.218</b>